Insider Selling: Podlesak Dennis, Syndax Pharmaceuticals Inc [SNDX] Director divested 19,200 shares

Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Syndax Pharmaceuticals Inc shares valued at $304,170 were sold by Podlesak Dennis on Aug 18 ’25. At $15.84 per share, Podlesak Dennis sold 19,200 shares. The insider’s holdings dropped to 191,763 shares worth approximately $3.04 million following the completion of this transaction.

Also, Podlesak Dennis sold 19,200 shares, netting a total of over 298,408 in proceeds. Following the sale of shares at $15.54 each, the insider now holds 191,763 shares.

Before that, Podlesak Dennis had sold 19,200 shares from its account. In a trade valued at $272,521, the Director traded Syndax Pharmaceuticals Inc shares for $14.19 each. Upon closing the transaction, the insider’s holdings decreased to 19,200 shares, worth approximately $3.04 million.

As published in a research note from BTIG Research on August 05, 2025, Syndax Pharmaceuticals Inc [SNDX] has been retained to a Buy and the price target has been revised to $56. Analysts at Goldman started covering the stock with ‘”a Buy”‘ outlook in a report released in early July. As of October 24, 2024, UBS has initiated its “Buy” rating for SNDX. Earlier on June 28, 2024, Jefferies initiated its rating. Their recommendation was “a Buy” for SNDX stock.

Analyzing SNDX Stock Performance

On last trading session, Syndax Pharmaceuticals Inc [NASDAQ: SNDX] rose 0.64% to $15.84. The stock’s lowest price that day was $15.4318, but it reached a high of $16.0399 in the same session. During the last five days, there has been a surge of approximately 7.54%. Over the course of the year, Syndax Pharmaceuticals Inc shares have dropped approximately -22.73%. Shares of the company reached a 52-week high of $16.95 on 02/21/25 and a 52-week low of $8.58 on 05/15/25.

Support And Resistance Levels for Syndax Pharmaceuticals Inc (SNDX)

According to the 24-hour chart, there is a support level at 15.50, which, if violated, would cause prices to drop to 15.16. In the upper region, resistance lies at 16.11. The next price resistance is at 16.38. RSI (Relative Strength Index) is 78.38 on the 14-day chart, showing overbought technical sentiment.

Is Syndax Pharmaceuticals Inc subject to short interest?

Stocks of Syndax Pharmaceuticals Inc saw a sharp rise in short interest on 2025-07-31 jumping by 34893.0 shares to 23.9 million. Data from Yahoo Finance shows that the short interest on 2025-06-30 was 23.87 million shares. A jump of 0.15% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 13.24 of the overall float, the days-to-cover ratio (short ratio) jumped to 13.24.

Which companies own the most shares of Syndax Pharmaceuticals Inc (SNDX)?

In terms of Syndax Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 26.5 in the next 12 months, up nearly 68.36% from the previous closing price of $15.74. Analysts anticipate Syndax Pharmaceuticals Inc stock to reach 35 by 2025, with the lowest price target being 18. In spite of this, 4 analysts ranked Syndax Pharmaceuticals Inc stock as Buy at the end of 2025. On January 31, 2024, Scotiabank assigned a price target of “a Sector perform” to the stock and downgraded coverage with a $23.

Most Popular

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.